Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biohaven Ltd. Common Shares (NY: BHVN )

36.26 +0.92 (+2.60%)
Official Closing Price Updated: 7:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biohaven Ltd. Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
BHVN Stock Earnings: Biohaven Misses EPS for Q1 2024
BHVN stock results show that Biohaven missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Shhh! 3 Secret Biotech Stocks Flying Below Wall Street’s Radar
These biotech stocks seem to be rich with intriguing growth plays going for very reasonable multiples this May. 
Via InvestorPlace
Around $1M Bet On Biohaven? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
3 Biotech Stocks to Buy on the Dip: April 2024
With medical innovation being a resilient space, investors can have confidence with these biotech stocks to buy on the dip. 
Via InvestorPlace
Why Is Obesity Drug Developer Altimmune Stock Trading Lower On Wednesday?
Latest findings on Altimmune's pemvidutide on body composition: lean mass preservation, significant weight loss from adipose tissue, and results in obesity and Metabolic dysfunction-associated... 
Via Benzinga
Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly
Biohaven's approach to combat obesity. Learn about their experimental drug taldefgrobep alfa (t-alpha), targeting muscle growth regulation for effective weight loss. CEO Vlad Coric discusses its... 
Via Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic... 
Via Benzinga
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) is a Stock Spotlight on 3/8
Via Investor Brand Network
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) is a Stock Spotlight on 3/4
Via Investor Brand Network
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy. 
Via Investor's Business Daily
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset... 
Via Benzinga
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs
The best weight-loss drug stocks firms improving the drugs or developing new, potentially superior weight-loss treatments. 
Via InvestorPlace
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) is a Stock Spotlight on 1/5
Via Investor Brand Network
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Based on good technical signals, BIOHAVEN LTD is potentially setting up for a breakout.
BIOHAVEN LTD (NYSE:BHVN) showing some interesting technicals. Here's why. 
Via Chartmill
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) Sets New 52-Week High in Monday Session
Via Investor Brand Network
Biohaven Ltd. (NYSE: BHVN) Records 52-Week High Thursday Morning
Via Investor Brand Network
Stock Market Rally Attempt Underway; Micron, Nike, Amazon, Meta In Focus: Weekly Review
But it's not a confirmed uptrend yet. Nike, Amazon and Meta were in focus. 
Via Investor's Business Daily
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Investors are constantly on the hunt for undervalued, under-followed, and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
What's Going On Pfizer's Subsidiary Biohaven Stock?
Pfizer Inc's (NYSE: PFE) subsidiary Biohaven Ltd (NYSE: BHVN) released an  
Via Benzinga
Why Sharps Technology Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers 
Via Benzinga
Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29%
The companies hope by lowering immunoglobulin G, an antibody, that they can treat myriad autoimmune diseases. 
Via Investor's Business Daily
Why Biohaven Stock Is Skyrocketing Today
Promising clinical trial data led investors to bid the stock up, adding to its solid year-to-date gain. 
Via The Motley Fool
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
MillerKnoll, Hayward Holdings, Ginkgo Bioworks And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 40 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
US Stocks Open Higher; Costco Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 50 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.14% to 33,664.90 while the NASDAQ... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Cramer Warns Investors About This AI Company Up 146% YTD: 'Too Much Hype, Too Much Fluff'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Micron Technology, Inc. (NASDAQ: MU) is "coming out of the trough, I agree with the hype. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.